Global Pharmacogenomics Market, by Technology Type (Polymerase Chain Reaction, Sequencing, Microarray, and Other Technologies), and by Application (Drug Discovery and Therapeutic Application) and by Geography - Trends and Forecast to 2025

Pharmacogenomics Market: New Innovative Solution for Diverse Medical Applications

Pharmacogenomics deals with the influence of genetic variation on drug response in patients by correlating gene expression changes and Single-Nucleotide Polymorphisms (SNPs) with a drug's efficacy or toxicity. Growing concerns for the early identification of drug advertises, drug safety, and growing need for prompt compliance to regulatory guidelines have led the introduction of new technologies and methods by pharmaceutical manufacturers and other intermediaries. These advancements are expected to fuel adoption of pharmacogenomics technology during the forecast period. Pharmacogenomics has different restorative applications such as cardiology, oncology, neurological disorder, and pain management. In this manner, through further headways in this field, by enhancing drug safety, optimizing drug therapy with increasing patient compliance and further reducing healthcare costs is expected to result in the meteoric growth of the pharmacogenomics market over the forecast period.

Many government agencies are actively supporting the implementation of pharmacogenomics in drug development and surveillance, so that patients can benefit from advances in genomic science and technology. The government is also involved in funding companies that work to develop bioinformatics technology for precision medicine research applications. For instance, in 2017, Armonica Technologies, Inc. an Albuquerque based company received US$1.5 Mn from the states US $40 Mn catalyst fund. This fund is intended for seed early stage-companies in New Mexico that are involved in developing novel technologies. Clinically personalized medicine is also expected to provide tools that will enhance the traditional approaches for estimating the risk/benefit of an intervention in patients.

The global pharmacogenomics market was valued at US$ 7,623.9 million in 2016 and is expected to witness a CAGR of 7.6% during the forecast period (2017 – 2025).

 


Figure 1. Global Pharmacogenomics Market Share, by Technology Type (%)

Pharmacogenomics Market

                     Source: Coherent Market Insights Analysis (2017)

Increasing demand for various techniques to pinpointing diagnoses down to the subtype of chronic conditions will drive the pharmacogenomics market

Increasing number of research studies pertaining to sequencing, especially next generation sequencing, are expected to increase demand for pharmacogenomics tests. Meteoric progress in the aspects of NGS technology, platform, and data analysis solutions is propelling widespread, as it shows valid results for problematic areas that have long plagued the drug development industry. Increasing prevalence of several infectious and non-infectious diseases is also one of the major factors boosting the demand for regulated next-generation sequencing-based clinical trial assays and companion diagnostics. According to U.S. Food and Drug Administration (FDA) statistics, over 100,000 people in the U.S. die each year from injurious responses to drugs that were correctly prescribed by a physician. Additionally, over 2.2 million people endure acute, though not fatal, side effects. Worldwide, BioWorld estimates those figures increase to 200,000 deaths and over 4.5 million people suffering serious side effects. Pharmacogenomics tests are expected to predict susceptibility to maladies as well as create therapeutics tailored to an individual's specific genetic profile. This in turn, is expected to increase market growth. However, unavailability of proper diagnostic testing due to lack of trained personnel, high costs associated with tests, dearth of laboratory facility, and lack of standardization and validation of the test procedures hampers the development of the personalized medicine.

Technological advancements leading to new product launch is a prominent factor fueling market growth

Today, screening of known polymorphic drug metabolism enzymes and transporters (DMET) is rapidly becoming routine practice in clinical research. So manufacturers are currently focusing on various approaches to pharmacogenomics analysis to provide rapid and cost-effective solutions for both the screening of known polymorphisms and discovery of novel variants. The combination of goldstandard Applied Biosystems TaqMan Assays with the high-throughput Applied Biosystems Open Array manufactured by Thermo Fisher Scientific Inc., enables analysis of common variants, typically in under four hours with the flexibility to modify array content.

North America held the largest market share, followed by Europe in 2016, owing to presence of major key players and strategic collaborations among them.  Asia Pacific is also expected to grow at a substantial rate due to increased investments in R&D and setting up of in-house manufacturing and R&D facilities. In 2008, Transgenomic entered into a laboratory services agreement with the Guangzhou Family Planning Center in Guangzhou, China to provide pharmacogenomic analyses within the Guangzhou Laboratory for pharmaceutical companies who choose to pursue clinical trials in China. Latin America and Africa are expected to grow at a steady pace, as countries in these regions have shown considerable interest in research and continuous efforts made by major players to expand their business in these regions. South African Medical Research Council (SAMRC) has collaborated with Beijing Genomics Institute in April 2017, to understand the genetic composition of the population, which is expected to augment growth of the pharmacogenomics in South Africa.

The market is driven by collaborations and pipelines for upcoming products. Objective of the collaborations between the organization and the companies is identification of specific tumor targets by expansion of known mutations associated with defective DNA repair. Companies are engaged in development of single comprehensive tests that can capture a large amount of relevant content. For instance, in 2017, Qiagen N.V. and Bristol-Myers Squibb signed an agreement for use of Next Generation Sequencing technology to develop gene expression profiles for immuno-oncology therapies.

Pharmacogenomics is an essential research area for development of medication for pain, cancer, psychotropic, and cardiovascular disease. The success of this medication is possible through the use of innovative technologies that help define the dosage setting for subsets of the population and an individual’s response to a specific drug. The success of the precision medicine is possible through the application of pharmacogenomics that uses information about a person’s genes, enzyme activities, cellular environment, and proteins to diagnose and treat diseases. Rapid advancements in groups of specialized molecular diagnostic tests is contributing to the improvement for assessment of real-time treatment of diseases.

Market Dynamics

Major factors that propel the market are increasing demand for personalized drugs, increasing prevalence of several non-infectious and infectious diseases, rising utilization of these technology for effective treatment therapeutics, and growing awareness about benefits associated with pharmacogenomics. Continuous collaboration among pharmacogenomics manufacturers for various applications in clinical and translational research is also expected to drive growth of the market across regions. In 2016, Merck & Co. Inc., collaborated with Biocartis, an innovative molecular diagnostic company to develop and commercialize a new liquid biopsy technology for RAS biomarker testing. This can enable more access to the test for number of metastatic colorectal cancer patients. Furthermore, use of pharmacogenomics to perform diagnostic assays in the field of determining individual’s susceptibility to certain diseases, toxicology, biochemical genetics, and drug safety are also expected to lead to rapid growth of the market for pharmacogenomics over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of pharmacogenomics and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, regulatory scenario, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global pharmacogenomics market based on the following parameters – company overview, financial performance, geographical presence, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Bayer AG, AstraZeneca plc, Assurex Health, GE Healthcare, Bristol-Myers Squibb Company, Qiagen, Inc., F. Hoffmann-La Roche Ltd, Transgenomic, Inc., Abbott Laboratories, Inc., and GlaxoSmithKline
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics
  • The global pharmacogenomics market report caters to various stakeholders in this industry including investors, researchers, pharmacogenomics manufacturers, new entrants, and financial analysts.
  • Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the pharmacogenomics market.

Detailed Segmentation:

  • Global Pharmacogenomics Market, By Technology Type:
    • Polymerase Chain Reaction
      • Sequencing
      • Microarray
      • Other Technologies
  • Global Pharmacogenomics Market, By Application:
    • Drug Discovery
    • Therapeutic Application
        • Oncology
        • Cardiology
        • Pain Management
        • Neurological Disorders
        • Others
  • Global Pharmacogenomics Market, By Geography:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Technology Type:
        • Polymerase Chain Reaction
        • Sequencing
        • Microarray
        • Other Technologies
      • By Application:
        • Drug Discovery
        • Therapeutic Application
          • Oncology
          • Cardiology
          • Pain Management
          • Neurological Disorders
          • Others
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Technology Type:
        • Polymerase Chain Reaction
        • Sequencing
        • Microarray
        • Other Technologies
      • By Application:
        • Drug Discovery
        • Therapeutic Application
          • Oncology
          • Cardiology
          • Pain Management
          • Neurological Disorders
          • Others
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
      • By Technology Type:
        • Polymerase Chain Reaction
        • Sequencing
        • Microarray
        • Other Technologies
      • By Application:
        • Drug Discovery
        • Therapeutic Application
          • Oncology
          • Cardiology
          • Pain Management
          • Neurological Disorders
          • Others
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Rest of Latin America
      • By Technology Type:
        • Polymerase Chain Reaction
        • Sequencing
        • Microarray
        • Other Technologies
      • By Application:
        • Drug Discovery
        • Therapeutic Application
          • Oncology
          • Cardiology
          • Pain Management
          • Neurological Disorders
          • Others
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Technology Type:
        • Polymerase Chain Reaction
        • Sequencing
        • Microarray
        • Other Technologies
      • By Application:
        • Drug Discovery
        • Therapeutic Application
          • Oncology
          • Cardiology
          • Pain Management
          • Neurological Disorders
          • Others
    • Africa
      • By Country:
        • North Africa
        • Central Africa
        • South Africa
      • By Technology Type:
        • Polymerase Chain Reaction
        • Sequencing
        • Microarray
        • Other Technologies
      • By Application:
        • Drug Discovery
        • Therapeutic Application
          • Oncology
          • Cardiology
          • Pain Management
          • Neurological Disorders
          • Others
  • Company Profiles
    •  Thermo Fisher Scientific Inc.*
      • Company Overview
      • Technology Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • Bayer AG
    • AstraZeneca plc
    • Assurex Health
    • GE Healthcare
    • Bristol-Myers Squibb Company
    • Qiagen, Inc.
    • Hoffmann-La Roche Ltd
    • Transgenomic, Inc.
    • Abbott Laboratories, Inc.
    • GlaxoSmithKline

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Technology Type
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
        • Supply Side Drivers
        • Demand Side Drivers
        • Economic Drivers
      • Restraints
      • Market Opportunities
      • Impact Analysis
      • Epidemiology
      • Regulatory Scenario
      • Industry Trends
      • PEST Analysis
  4. Global Pharmacogenomics Market, By Technology Type, 2017 - 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 - 2025
      • Segment Trends
    • Polymerase Chain Reaction
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
    • Sequencing
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
    • Microarray
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
    • Other Technologies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  5. Global Pharmacogenomics Market, By Application, 2017 - 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 - 2025
      • Segment Trends
    • Drug Discovery
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
    • Therapeutic Application
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
        • Oncology
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
        • Cardiology
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
        • Pain Management
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
        • Neurological Disorders
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  1. Global Pharmacogenomics Market, By Regions, 2017 - 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, By Regions, 2017 - 2025
    • North America
      • Market Size and Forecast, By Technology, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Technology, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Technology, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Technology, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
        • Brazil
        • Mexico
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Technology, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
        • Northern Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Technology, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profiles
      • Bayer AG
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Thermo Fisher Scientific Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • AstraZeneca plc
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Assurex Health
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GE Healthcare
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Bristol-Myers Squibb Company
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Qiagen, Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • F. Hoffmann-La Roche Ltd
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Transgenomic, Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Abbott Laboratories, Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GlaxoSmithKline
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
  3. Section
    • References
    • Analyst Views
    • Research Methodology
    • About Us and Sales Contact

*Browse 29 market data tables and 33 figures on "Pharmacogenomics Market - Global forecast to 2025”.

 

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.